ArticleNucleic acids research2025
A solid-phase enzymatic synthesis platform for the facile production of 2'-fluoroarabinonucleic acid (FANA) and chimeric XNA oligonucleotides using an evolved XNA polymerase.
Article in Nucleic acids research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Engineered polymerase-mediated efficient synthesis of site-specifically functionalized RNA and 2'-modified RNA oligonucleotides via genetic alphabet expansion.Nature communications · 2026Article
- Single-residue engineering of Klenow fragment enables broad acceptance of chemically modified nucleotides.Nucleic acids research · 2026Article
- From machine learning to multimodal models: The AI revolution in enzyme engineering.Biodesign research · 2026Review
- Enzymatic Synthesis of Mixed XNA Polymers Containing 2'Fluoro and 2'Azide Modifications.ACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Xenobiotic nucleic acids (XNAs) significantly expand the range of genetic polymers and serve as promising alternatives to DNA and RNA for numerous biological applications. However, the extensive exploration and application of XNAs are limited by low sustainability and yields in solid-phase oligonucleotide synthesis, as well as by the unavailability of efficient XNA polymerases for polymerase-mediated XNA production. To address the limitations in XNA production, we developed a solid-phase enzymatic XNA oligonucleotide synthesis platform using a laboratory-evolved XNA polymerase, SFM5-7, which exhibits excellent activity for synthesizing DNA, RNA, 2'-fluoroarabinonucleic acid (FANA), and other 2'-modified XNA oligonucleotides. This platform employs ribonucleotide insertion and alkaline cleavage of the oligonucleotide product before and after SFM5-7-mediated XNA synthesis, enabling recycled XNA synthesis through the reuse of a bead-immobilized self-priming hairpin DNA template. The platform's potential and versatility are demonstrated by the production of FANA, 2'-modified RNAs, chimeric XNAs, 5'-end-labeled FANA, and an active FANAzyme. This platform should facilitate the customized production of functional XNAs with programmable modifications, accelerating their applications in biotechnology and biomedicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.